Skip to main content
OpenTrials
Completed

NCT Number: NCT02756546

Circulating MicroRNAs in Understanding Pathogenesis of Systemic Lupus Erythematosis

This study aims to identify the expression signature of miR-181a, miR-196a and miR-21 in plasma of SLE patients and difference in their expression among groups with different systemic lupus erythematosis disease activity index (SLEDAI) scores.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Systemic Lupus Erythematosis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult systemic lupus erythematosis patients

Exclusion criteria

  • Patients younger than 18 years, patients with other autoimmune diseases or malignancy.

Treatment and study plan

Cyclophosphamide

Drug

Hydroxychloroquine

Drug

Hydrocortisone

Drug

Primary outcomes

  1. MicroRNAs expression level

    Time frame: 3 months

Sponsors and collaborators

Lead sponsor

Cairo University

Other

Registry information

Important dates

Study start
2014
Primary completion
2015
Study completion
2015
First posted
Apr 29, 2016
Registry last updated
Apr 29, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.